Clinical Trials Logo

Clinical Trial Summary

This is a prospective, pilot trial to evaluate the safety and effectiveness of The Paragonix SherpaPak™ Cardiac Transport System ("SherpaPak CTS") in transportation of cardiac allografts recovered from donors after circulatory death with thoracoabdominal normothermic regional perfusion (TA-NRP). SherpaPak™ CTS is an ultraportable hypothermic preservation and transport system that has been approved by United States Food & Drug Administration (FDA) for clinical use in heart transplantation.

Clinical Trial Description

The investigators will accept donors between the ages of 18 and 49 without any known history of coronary artery disease, insulin dependent diabetes, or long-term smoking (>20 pack/years) and normal baseline cardiac function (EF>50) assessed with transthoracic echocardiogram. Donors will be selected and matched to the recipients based on standard criteria (blood group, cross-match, size match, and clinical stability). The current procedure of donation after circulatory death (DCD) and procurement follows a well-established course. After consent is obtained, the organs are allocated through United Network for Organ Sharing (UNOS). All organs will be recovered with protocolized UNMC DCD TA-NRP technique that involves reestablishment of blood flow in-situ after donor's circulatory arrest using portable venoarterial extracorporeal membrane oxygenation (VA-ECMO). Organs will be transported from a donor site to recipient center with the SherpaPak™ CTS. All organs will be transplanted at Nebraska Medicine. Recipients ("subjects") will be followed from transplant through one-year post-transplantation. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05038943
Study type Interventional
Source University of Nebraska
Contact Rachel E Halstead (Gross), RN, BSN
Phone 402-559-3665
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date September 1, 2021
Completion date September 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Recruiting NCT03766282 - Pharmacokinetics in Extracorporeal Membrane Oxygenation
Recruiting NCT03355625 - Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients
Completed NCT01521195 - Oxygen Consumption In Critically Ill Children N/A
Not yet recruiting NCT04990349 - Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock Phase 3
Recruiting NCT04536272 - Reduced Anticoagulation Targets in ECLS (RATE) Phase 3
Completed NCT03764319 - Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With ARDS and ECMO N/A
Completed NCT02995811 - Characterising Changes in Muscle Quantity and Quality in Patients Requiring ECMO Oxygen During Critical Illness
Recruiting NCT04754854 - Reduction of Blood Recirculation in Veno-Venous ECMO
Completed NCT03607760 - Extracorporeal Membrane Oxygenation (ECMO)
Completed NCT03131063 - Pharmacokinetic Study of Antibiotics in Patients Assisted by Extracorporeal Membrane Oxygenation (PHARMECMO) N/A
Completed NCT04405973 - Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMO
Completed NCT03065647 - ECPR for Refractory Out-Of-Hospital Cardiac Arrest N/A
Recruiting NCT02748668 - Extracorporeal Membrane Oxygenation: Blood Cells N/A
Not yet recruiting NCT04620070 - ON-SCENE Initiation of Extracorporeal CardioPulmonary Resuscitation During Refractory Out-of-Hospital Cardiac Arrest N/A
Recruiting NCT03583970 - Veno-arterial Extracorporeal Membrane Oxygenation Prior to Left Ventricular Assist Device Implantation.
Completed NCT03208270 - Antithrombin Supplementation in ECMO Phase 2/Phase 3
Recruiting NCT02895373 - PGE1 as Additive Anticoagulant in ECMO-Therapy Phase 2
Completed NCT01903863 - The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity N/A